InflaRx N.V. (NASDAQ:IFRX) Receives Average Recommendation of “Moderate Buy” from Analysts

InflaRx N.V. (NASDAQ:IFRX) has earned an average recommendation of “Moderate Buy” from the seven analysts that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $7.00.

IFRX has been the subject of several research reports. Raymond James Financial upgraded InflaRx from an “outperform” rating to a “strong-buy” rating and raised their target price for the company from $7.00 to $9.00 in a research note on Wednesday, May 13th. Wall Street Zen upgraded InflaRx from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Oppenheimer initiated coverage on InflaRx in a research note on Friday, April 24th. They issued an “outperform” rating and a $5.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of InflaRx in a report on Friday, March 27th. Finally, Guggenheim reiterated a “buy” rating and issued a $14.00 target price on shares of InflaRx in a report on Tuesday, April 21st.

InflaRx Stock Down 2.9%

Shares of NASDAQ IFRX opened at $1.66 on Wednesday. The firm has a market cap of $120.00 million, a PE ratio of -2.34 and a beta of 2.42. The company’s fifty day simple moving average is $1.83 and its 200 day simple moving average is $1.29. InflaRx has a 12-month low of $0.74 and a 12-month high of $2.95.

InflaRx (NASDAQ:IFRX) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.08. On average, equities analysts predict that InflaRx will post -0.4 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of IFRX. Suvretta Capital Management LLC lifted its stake in shares of InflaRx by 22.4% in the fourth quarter. Suvretta Capital Management LLC now owns 7,933,910 shares of the company’s stock valued at $8,013,000 after buying an additional 1,450,000 shares in the last quarter. 683 Capital Management LLC increased its position in shares of InflaRx by 47.3% during the fourth quarter. 683 Capital Management LLC now owns 3,315,000 shares of the company’s stock worth $3,348,000 after acquiring an additional 1,065,000 shares in the last quarter. Bank of America Corp DE acquired a new stake in shares of InflaRx in the 3rd quarter worth about $3,316,000. Eversept Partners LP raised its holdings in shares of InflaRx by 1.5% in the 4th quarter. Eversept Partners LP now owns 1,757,312 shares of the company’s stock worth $1,775,000 after acquiring an additional 26,677 shares during the last quarter. Finally, Woodline Partners LP bought a new position in InflaRx in the 1st quarter valued at about $766,000. Institutional investors and hedge funds own 42.39% of the company’s stock.

InflaRx Company Profile

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.